



An die interessierte Partei / To whom it may concern

Dr. Stefan Dreiheller
Quality Unit / Regulatory Affairs

Date of issue: 20.09.2018
Page 1/1
Doc.-No. EIP-1011
Revision 6

California Proposition 65

MEGGLE products:

- Lactose Monohydrate Ph. Eur. / USP-NF / JP: CapsuLac[®] 60, FlowLac[®] 90, FlowLac[®] 100, GranuLac[®] 70, GranuLac[®] 140, GranuLac[®] 200, GranuLac[®] 230, PrismaLac[®] 40, SacheLac[®] 80, SorboLac[®] 400, SpheroLac[®] 100, Tablettose[®] 70, Tablettose[®] 80, Tablettose[®] 100
- Lactose Monohydrate USP-NF / Ph. Eur. / JP: InhaLac[®] 70, InhaLac[®] 120, InhaLac[®] 160, InhaLac[®] 230, InhaLac[®] 250, InhaLac[®] 251, InhaLac[®] 400, InhaLac[®] 500, Lactose monohydrate Low Endotoxin
- Anhydrous Lactose USP-NF / Ph. Eur. / JP: DuraLac[®] H

Substances known to the State of California to cause cancer or birth defects or other reproductive harm are not used for the production of above mentioned products.

The above mentioned products are safe as pharmaceutical excipient and as food (milk sugar).

Residues and contaminants in above mentioned products are monitored. The products comply with the relevant pharmaceutical monographs and food laws and cause no significant risk of harm when they are used.

Freundliche Grüße / Best regards


Dr. Stefan Dreiheller